Clinical TrialAug 11, 2026, 08:06 AM
Clearmind Intranasal MEAI Study Shows Positive Permeation Results
AI Summary
Clearmind Medicine Inc. announced positive permeation study results for its intranasal MEAI development program, confirming that enhanced nasal residence time does not compromise the drug's permeation characteristics. The studies showed rapid and extensive permeation, with cumulative permeation reaching 97.35% for the intranasal formulation and 98.34% for the conventional solution by 180 minutes. These findings support the continued development of MEAI as a differentiated therapeutic candidate for mental health disorders, including alcohol use disorder, weight management, obesity, and metabolic conditions, by demonstrating effective drug delivery while maintaining prolonged contact with nasal tissue.
Key Highlights
- Intranasal MEAI permeation reached 97.35% by 180 minutes.
- Conventional MEAI permeation reached 98.34% by 180 minutes.
- Enhanced nasal residence time does not compromise permeation characteristics.
- Formulation compatibility achieved for intranasal MEAI platform.
- Intranasal MEAI showed substantially longer nasal retention than conventional solution.
- Preserved permeation kinetics maintained with extended nasal residence time.
- Findings support MEAI as a therapeutic for alcohol use disorder and weight management.
Price Impact
More from CMND